Polycystic ovary syndrome: What to say when asked about the chance of pregnancy

IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Laure Morin-Papunen, Sari Pelkonen, Terhi Piltonen
{"title":"Polycystic ovary syndrome: What to say when asked about the chance of pregnancy","authors":"Laure Morin-Papunen,&nbsp;Sari Pelkonen,&nbsp;Terhi Piltonen","doi":"10.1111/aogs.15149","DOIUrl":null,"url":null,"abstract":"<p>Polycystic ovary syndrome (PCOS) was described as early as 1844 by the French doctor Chereau and later by Stein and Leventhal in 1935. PCOS is the most common hormonal disorder in women and affects 11%–15% of the female population. The syndrome is lifelong, characterized by hyperandrogenism, chronic oligo-anovulation, and high risk for several morbidities, and was long considered as an exclusively gynecological condition mainly affecting fertility.<span><sup>1, 2</sup></span> This is true as PCOS covers about 30% of cases of infertility and 80% of cases with anovulatory infertility. Conversely, about 70%–80% of all women with PCOS have been estimated to suffer from infertility.<span><sup>1, 2</sup></span> In addition to anovulation, an endometrial component seems to contribute to infertility and poor reproductive outcomes in affected women.<span><sup>3</sup></span></p><p>It is generally accepted that PCOS affects fertility, and many women with PCOS are highly concerned about their reproductive capacity, often having a fear of remaining childless. However, results in general population studies have displayed some uncertainty of results on fecundity in PCOS, mainly due to differences in study population, length of follow-up, and, in some studies, lack of adjustments for confounding factors, such as obesity, male infertility, or use of assisted reproductive technologies (ART).<span><sup>4-7</sup></span> In three population-based studies,<span><sup>4-6</sup></span> the overall fertility rate in women with PCOS was decreased,<span><sup>4, 5</sup></span> and the women were more often nulliparous at an advanced age compared to other women.<span><sup>6</sup></span> Moreover, the women ended up having their children older and eventually had fewer children compared to women without the syndrome, with a lower probability of having three or more children.<span><sup>5, 6</sup></span> However, a Swedish register study<span><sup>7</sup></span> and a population study from Finland<span><sup>6</sup></span> showed that women with PCOS had a chance of having at least one child similar to that of other women and that their cumulative probability of childbirth was as high as in other women, especially if ART were available, as is the case in Nordic countries.</p><p>One explanation for the good reproductive capacity of women affected may be the increased ovarian reserve as shown by high serum anti-Müllerian hormone (AMH) levels. However, PCOS characteristics, including menstrual cycles and systemic AMH levels, change with aging as the ovarian reserve and hormonal activity decrease, enabling a new, more optimal hormonal balance. Women with PCOS start gaining more regular cycles around the age of 35 years and may have an improved chance to conceive naturally.<span><sup>8</sup></span> Conversely, this feature should be better recognized in women with PCOS over 40 years of age, as it may also lead to unplanned pregnancies especially if the women have considered themselves infertile their whole lives. To date, no data exist on induced abortions in PCOS.</p><p>Excess weight affects approximately 60%–70% of women with the syndrome, with large variation between individuals and geographic regions and ethnicity.<span><sup>1, 2</sup></span> However, weight gain usually starts in childhood.<span><sup>9</sup></span> Excess weight exacerbates insulin resistance with compensatory hyperinsulinemia and further development of the metabolic and reproductive disorders typical of PCOS. Obesity has direct effects both in the hypothalamic-ovarian axis and in endometrial function and diminishes the chance of conceiving.<span><sup>10</sup></span> Obesity also affects embryo quality.<span><sup>11</sup></span> In some societies, a high body mass index (BMI) also limits access to publicly funded fertility treatment, thus promoting childlessness in this patient group.</p><p>Hence, the treatment of obesity is crucial to enable optimal fertility for affected women. Lifestyle (diet and exercise) is the first-line management option and should always be a part of the PCOS management plan. In line, the new International PCOS Guidelines recommend pre-pregnancy treatment with lifestyle and/or the insulin sensitizer metformin, or obesity-targeting medications for all women with PCOS with BMI ≥ 25 kg/m<sup>2</sup>.<span><sup>12</sup></span> Unfortunately, the results of these interventions are still modest, as most women with PCOS and obesity regain weight within 2 years after the intervention. Besides bariatric surgery, the emergence of new anti-obesity glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has brought great expectations in this patient group. The latest products, such as the GLP-1 RAs and glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist tirzepatide, have weight loss outcomes comparable to those achieved with bariatric surgery. The use of GLP-1 RAs has been shown to induce significant improvements in insulin action, cardiovascular disease risk, weight reduction (including waist circumference), and reproductive function including increased pregnancy rates in overweight or obese PCOS women.<span><sup>13, 14</sup></span> However, it must be noted that GLP-1 receptor agonists are contraindicated during pregnancy. A recent meta-analysis elaborated the risk for malformations in offspring born from pregnancies that were subjected to obesity medications, and no major concerns were raised regarding increased malformation rates.<span><sup>15</sup></span> However, the weight gain after cessation of GLP-1 receptor agonists in early pregnancy is of concern. In clinical practice, gastrointestinal disturbances, including nausea, vomiting, and diarrhea, are the most common side effects and reasons for medication discontinuation. In general, caution is warranted regarding the long-term adverse effects of GLP-1 RAs, including gastrointestinal disturbances, hypoglycemia, and effect on pancreatic health. A regular follow-up with concomitant behavioral therapy to minimize weight regain has been shown to be successful and should always be implemented together with GLP-1 RA medication. In addition, optimizing dosing strategies, closely monitoring patients, and tailoring treatment to individual needs are essential to maximizing their benefits while minimizing their drawbacks.<span><sup>14, 16</sup></span> With the rapid rise of GLP-1 RA use worldwide and the emergence of even more efficient preparations, their role in the treatment of obesity prior to pregnancy, including in PCOS, is expected to grow exponentially. Further research is warranted in women with PCOS to validate the efficacy, safety, and long-term outcomes of these medications.</p><p>As an invasive treatment with small but real risks of complications, bariatric surgery is not the first-line treatment option for fertility issues for women with PCOS and obesity. However, bariatric surgery was recently included in the recommendations of the international evidence-based guidelines for PCOS<span><sup>12</sup></span> and, in Finland, the national guideline to treat obesity has included PCOS diagnosis as one of the key factors supporting the decision on bariatric surgery. Supporting this, a recent, large randomized controlled study (RCT) (the “BAMBIBI-trial”)<span><sup>17</sup></span> assigned eighty women in a 1:1 ratio to either vertical sleeve gastrectomy or behavioral interventions and medical therapy (metformin or orlistat). The women were followed for 52 weeks. As expected, women in the surgical group experienced more spontaneous biochemically confirmed ovulations (2.5 times more often) and restoration of spontaneous menses, which suggests improvement in spontaneous fertility in these women. Indeed, larger, long-lasting RCTs are required to further clarify the role of bariatric surgery in the treatment of reproductive disorders and pregnancy complications associated with PCOS as well as its safety regarding the health of the offspring.</p><p>In conclusion, what to say to a woman affected with PCOS when asked about the chance of pregnancy? First, as PCOS is a common condition with substantial effects on reproductive outcomes and is the most frequent cause of anovulatory infertility, the woman should be encouraged not to postpone pregnancy to be able to achieve the desired family size. Lifestyle intervention without stigmatizing the patient, promoting exercise alone or multicomponent management combining nutritional advice with exercise and behavioral strategies, together with metformin should be recommended. Information should also be given on the efficacy, but also on the short- and long-term adverse effects of second-line therapies, such as GLP1 RAs and bariatric surgery. On the other hand, healthcare providers should inform the patient that the good ovarian reserve in PCOS brings indisputable reproductive challenges but also advantages. Most importantly, with early and effective prevention and treatment of obesity and the use of ART, the patient should be informed that her chance of having at least one child is similar to that of women without the syndrome.</p>","PeriodicalId":6990,"journal":{"name":"Acta Obstetricia et Gynecologica Scandinavica","volume":"104 7","pages":"1228-1230"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aogs.15149","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Obstetricia et Gynecologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aogs.15149","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Polycystic ovary syndrome (PCOS) was described as early as 1844 by the French doctor Chereau and later by Stein and Leventhal in 1935. PCOS is the most common hormonal disorder in women and affects 11%–15% of the female population. The syndrome is lifelong, characterized by hyperandrogenism, chronic oligo-anovulation, and high risk for several morbidities, and was long considered as an exclusively gynecological condition mainly affecting fertility.1, 2 This is true as PCOS covers about 30% of cases of infertility and 80% of cases with anovulatory infertility. Conversely, about 70%–80% of all women with PCOS have been estimated to suffer from infertility.1, 2 In addition to anovulation, an endometrial component seems to contribute to infertility and poor reproductive outcomes in affected women.3

It is generally accepted that PCOS affects fertility, and many women with PCOS are highly concerned about their reproductive capacity, often having a fear of remaining childless. However, results in general population studies have displayed some uncertainty of results on fecundity in PCOS, mainly due to differences in study population, length of follow-up, and, in some studies, lack of adjustments for confounding factors, such as obesity, male infertility, or use of assisted reproductive technologies (ART).4-7 In three population-based studies,4-6 the overall fertility rate in women with PCOS was decreased,4, 5 and the women were more often nulliparous at an advanced age compared to other women.6 Moreover, the women ended up having their children older and eventually had fewer children compared to women without the syndrome, with a lower probability of having three or more children.5, 6 However, a Swedish register study7 and a population study from Finland6 showed that women with PCOS had a chance of having at least one child similar to that of other women and that their cumulative probability of childbirth was as high as in other women, especially if ART were available, as is the case in Nordic countries.

One explanation for the good reproductive capacity of women affected may be the increased ovarian reserve as shown by high serum anti-Müllerian hormone (AMH) levels. However, PCOS characteristics, including menstrual cycles and systemic AMH levels, change with aging as the ovarian reserve and hormonal activity decrease, enabling a new, more optimal hormonal balance. Women with PCOS start gaining more regular cycles around the age of 35 years and may have an improved chance to conceive naturally.8 Conversely, this feature should be better recognized in women with PCOS over 40 years of age, as it may also lead to unplanned pregnancies especially if the women have considered themselves infertile their whole lives. To date, no data exist on induced abortions in PCOS.

Excess weight affects approximately 60%–70% of women with the syndrome, with large variation between individuals and geographic regions and ethnicity.1, 2 However, weight gain usually starts in childhood.9 Excess weight exacerbates insulin resistance with compensatory hyperinsulinemia and further development of the metabolic and reproductive disorders typical of PCOS. Obesity has direct effects both in the hypothalamic-ovarian axis and in endometrial function and diminishes the chance of conceiving.10 Obesity also affects embryo quality.11 In some societies, a high body mass index (BMI) also limits access to publicly funded fertility treatment, thus promoting childlessness in this patient group.

Hence, the treatment of obesity is crucial to enable optimal fertility for affected women. Lifestyle (diet and exercise) is the first-line management option and should always be a part of the PCOS management plan. In line, the new International PCOS Guidelines recommend pre-pregnancy treatment with lifestyle and/or the insulin sensitizer metformin, or obesity-targeting medications for all women with PCOS with BMI ≥ 25 kg/m2.12 Unfortunately, the results of these interventions are still modest, as most women with PCOS and obesity regain weight within 2 years after the intervention. Besides bariatric surgery, the emergence of new anti-obesity glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has brought great expectations in this patient group. The latest products, such as the GLP-1 RAs and glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist tirzepatide, have weight loss outcomes comparable to those achieved with bariatric surgery. The use of GLP-1 RAs has been shown to induce significant improvements in insulin action, cardiovascular disease risk, weight reduction (including waist circumference), and reproductive function including increased pregnancy rates in overweight or obese PCOS women.13, 14 However, it must be noted that GLP-1 receptor agonists are contraindicated during pregnancy. A recent meta-analysis elaborated the risk for malformations in offspring born from pregnancies that were subjected to obesity medications, and no major concerns were raised regarding increased malformation rates.15 However, the weight gain after cessation of GLP-1 receptor agonists in early pregnancy is of concern. In clinical practice, gastrointestinal disturbances, including nausea, vomiting, and diarrhea, are the most common side effects and reasons for medication discontinuation. In general, caution is warranted regarding the long-term adverse effects of GLP-1 RAs, including gastrointestinal disturbances, hypoglycemia, and effect on pancreatic health. A regular follow-up with concomitant behavioral therapy to minimize weight regain has been shown to be successful and should always be implemented together with GLP-1 RA medication. In addition, optimizing dosing strategies, closely monitoring patients, and tailoring treatment to individual needs are essential to maximizing their benefits while minimizing their drawbacks.14, 16 With the rapid rise of GLP-1 RA use worldwide and the emergence of even more efficient preparations, their role in the treatment of obesity prior to pregnancy, including in PCOS, is expected to grow exponentially. Further research is warranted in women with PCOS to validate the efficacy, safety, and long-term outcomes of these medications.

As an invasive treatment with small but real risks of complications, bariatric surgery is not the first-line treatment option for fertility issues for women with PCOS and obesity. However, bariatric surgery was recently included in the recommendations of the international evidence-based guidelines for PCOS12 and, in Finland, the national guideline to treat obesity has included PCOS diagnosis as one of the key factors supporting the decision on bariatric surgery. Supporting this, a recent, large randomized controlled study (RCT) (the “BAMBIBI-trial”)17 assigned eighty women in a 1:1 ratio to either vertical sleeve gastrectomy or behavioral interventions and medical therapy (metformin or orlistat). The women were followed for 52 weeks. As expected, women in the surgical group experienced more spontaneous biochemically confirmed ovulations (2.5 times more often) and restoration of spontaneous menses, which suggests improvement in spontaneous fertility in these women. Indeed, larger, long-lasting RCTs are required to further clarify the role of bariatric surgery in the treatment of reproductive disorders and pregnancy complications associated with PCOS as well as its safety regarding the health of the offspring.

In conclusion, what to say to a woman affected with PCOS when asked about the chance of pregnancy? First, as PCOS is a common condition with substantial effects on reproductive outcomes and is the most frequent cause of anovulatory infertility, the woman should be encouraged not to postpone pregnancy to be able to achieve the desired family size. Lifestyle intervention without stigmatizing the patient, promoting exercise alone or multicomponent management combining nutritional advice with exercise and behavioral strategies, together with metformin should be recommended. Information should also be given on the efficacy, but also on the short- and long-term adverse effects of second-line therapies, such as GLP1 RAs and bariatric surgery. On the other hand, healthcare providers should inform the patient that the good ovarian reserve in PCOS brings indisputable reproductive challenges but also advantages. Most importantly, with early and effective prevention and treatment of obesity and the use of ART, the patient should be informed that her chance of having at least one child is similar to that of women without the syndrome.

多囊卵巢综合征:当被问及怀孕的机会时该说什么?
多囊卵巢综合征(PCOS)最早于1844年由法国医生Chereau描述,后来由Stein和Leventhal于1935年描述。多囊卵巢综合征是女性中最常见的荷尔蒙失调,影响11%-15%的女性人口。该综合征是终身性的,特点是雄激素过多,慢性少排卵,几种发病率高,长期以来被认为是一种专门的妇科疾病,主要影响生育。这是事实,因为多囊卵巢综合征约占30%的不孕症病例和80%的无排卵性不孕症病例。相反,据估计,大约70%-80%的多囊卵巢综合征女性患有不孕症。1,2除了不排卵外,子宫内膜成分似乎也会导致不孕和受影响妇女的不良生殖结果。人们普遍认为多囊卵巢综合征会影响生育能力,许多患有多囊卵巢综合征的女性高度关注自己的生育能力,经常害怕没有孩子。然而,一般人群研究的结果显示PCOS的生育能力存在一定的不确定性,这主要是由于研究人群、随访时间的差异,以及一些研究缺乏对混杂因素的调整,如肥胖、男性不育或辅助生殖技术(ART)的使用。在三项基于人群的研究中,4-6多囊卵巢综合征妇女的总体生育率下降了,4,5,与其他妇女相比,这些妇女在高龄时更常不能生育6此外,与没有这种症状的女性相比,这些女性生孩子的年龄更大,最终生孩子的数量更少,生三个或更多孩子的可能性更低。然而,瑞典的一项登记研究和芬兰的一项人口研究表明,患有多囊卵巢综合征的妇女有机会至少生一个与其他妇女相似的孩子,而且她们的累计分娩概率与其他妇女一样高,特别是在有抗逆转录病毒治疗的情况下,就像北欧国家的情况一样。对受影响女性良好生殖能力的一种解释可能是卵巢储备增加,如血清抗<s:1>勒氏杆菌激素(AMH)水平高所示。然而,PCOS的特征,包括月经周期和全身AMH水平,随着年龄的增长而改变,卵巢储备和激素活性下降,从而实现新的,更理想的激素平衡。患有多囊卵巢综合征的女性在35岁左右开始获得更有规律的月经周期,自然怀孕的机会可能会增加相反,在40岁以上的多囊卵巢综合征患者中应该更好地认识到这一特征,因为它也可能导致计划外怀孕,特别是如果女性认为自己一生都不能生育。到目前为止,还没有关于多囊卵巢综合征患者人工流产的数据。体重过重影响约60%-70%患有该综合征的妇女,个体、地理区域和种族之间存在很大差异。然而,体重增加通常从童年开始超重加重胰岛素抵抗,伴代偿性高胰岛素血症,进一步发展多囊卵巢综合征典型的代谢和生殖障碍。肥胖对下丘脑-卵巢轴和子宫内膜功能都有直接影响,并降低了怀孕的机会肥胖也会影响胚胎质量在一些社会中,高身体质量指数(BMI)也限制了获得公共资助的生育治疗,从而促进了这一患者群体的不孕。因此,治疗肥胖对于使受影响的妇女获得最佳生育能力至关重要。生活方式(饮食和运动)是第一线的管理选择,应该始终是多囊卵巢综合征管理计划的一部分。与此一致,新的国际多囊卵巢综合征指南推荐所有BMI≥25 kg/m2的多囊卵巢综合征妇女孕前治疗采用生活方式和/或胰岛素增敏剂二甲双胍,或肥胖靶向药物。不幸的是,这些干预的结果仍然是温和的,因为大多数多囊卵巢综合征和肥胖妇女在干预后2年内体重恢复。除减肥手术外,新型抗肥胖胰高血糖素样肽1受体激动剂(GLP-1 RAs)的出现给这一患者群体带来了很大的期望。最新的产品,如GLP-1 RAs和葡萄糖依赖性胰岛素性多肽(GIP)受体双激动剂tizepatide,具有与减肥手术相当的减肥效果。使用GLP-1 RAs已被证明可显著改善胰岛素作用、心血管疾病风险、体重减轻(包括腰围)和生殖功能,包括增加超重或肥胖多囊卵巢综合征妇女的怀孕率。13,14然而,必须注意的是,GLP-1受体激动剂在怀孕期间是禁忌的。 最近的一项荟萃分析详细阐述了服用减肥药的孕妇所生后代的畸形风险,并没有对畸形率的增加提出重大担忧然而,妊娠早期停用GLP-1受体激动剂后的体重增加值得关注。在临床实践中,胃肠道紊乱,包括恶心、呕吐和腹泻,是最常见的副作用和停药的原因。总的来说,对于GLP-1 RAs的长期不良反应,包括胃肠道紊乱、低血糖和对胰腺健康的影响,需要谨慎对待。定期随访并辅以行为治疗以减少体重反弹已被证明是成功的,并且应始终与GLP-1 RA药物一起实施。此外,优化给药策略,密切监测患者,并根据个人需求定制治疗,对于最大限度地发挥其益处,同时最大限度地减少其缺点至关重要。14,16随着GLP-1 RA在世界范围内使用的迅速增加和更有效制剂的出现,它们在治疗孕前肥胖,包括多囊卵巢综合征中的作用有望呈指数级增长。需要对多囊卵巢综合征患者进行进一步的研究,以验证这些药物的有效性、安全性和长期疗效。作为一种侵入性治疗,虽然并发症的风险很小,但减肥手术并不是多囊卵巢综合征和肥胖女性生育问题的一线治疗选择。然而,减肥手术最近被列入国际PCOS循证指南的建议中,在芬兰,国家肥胖治疗指南已将PCOS诊断作为支持减肥手术决定的关键因素之一。最近的一项大型随机对照研究(RCT)(“bambibi试验”)支持这一观点,将80名妇女按1:1的比例分配到垂直袖胃切除术或行为干预和药物治疗(二甲双胍或奥利司他)。这些女性被跟踪了52周。正如预期的那样,手术组的女性经历了更多的自发生化确认排卵(2.5倍以上)和自然月经的恢复,这表明这些女性的自然生育能力得到了改善。事实上,需要更大规模、更长期的随机对照试验来进一步阐明减肥手术在治疗与多囊卵巢综合征相关的生殖障碍和妊娠并发症中的作用,以及其对后代健康的安全性。综上所述,当被问及多囊卵巢综合征患者怀孕的可能性时,该如何回答?首先,由于多囊卵巢综合征是一种对生殖结果有重大影响的常见疾病,是无排卵性不孕的最常见原因,应鼓励妇女不要推迟怀孕,以达到理想的家庭规模。生活方式干预不应使患者污名化,提倡单独运动或将营养建议与运动和行为策略相结合的多组分管理,并应推荐二甲双胍。还应提供有关疗效的信息,以及二线治疗(如GLP1 RAs和减肥手术)的短期和长期不良反应。另一方面,医疗保健提供者应告知患者,多囊卵巢综合征良好的卵巢储备带来了无可争议的生殖挑战,但也有优势。最重要的是,通过早期和有效的预防和治疗肥胖以及使用抗逆转录病毒治疗,患者应该被告知,她至少有一个孩子的机会与没有这种综合征的妇女相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.00
自引率
4.70%
发文量
180
审稿时长
3-6 weeks
期刊介绍: Published monthly, Acta Obstetricia et Gynecologica Scandinavica is an international journal dedicated to providing the very latest information on the results of both clinical, basic and translational research work related to all aspects of women’s health from around the globe. The journal regularly publishes commentaries, reviews, and original articles on a wide variety of topics including: gynecology, pregnancy, birth, female urology, gynecologic oncology, fertility and reproductive biology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信